Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience - PubMed (original) (raw)
Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience
J R Yannelli et al. Int J Cancer. 1996.
Abstract
Between 1989 and 1993, 255 tumor biopsies representing 4 tumor histologies (melanoma, breast cancer, colon cancer and renal cell cancer) were received by the Surgery Branch of the National Cancer Institute. Tumor-infiltrating lymphocytes (TIL) were grown from single-cell suspensions of tumor biopsies over the course of 30-45 days. The TIL were grown in medium containing IL-2. To obtain numbers suitable for therapy (>10(11)), TIL were expanded using a large-scale system of cell culture and harvesting. While the largest number of biopsies was obtained from melanoma patients, TIL were successfully grown from 160 of 255 tumor biopsies representing all 4 histologies. Under the culture conditions employed, several characteristics of TIL expansion were observed. The cell surface phenotype of TIL which grew out from the tumor biopsies was generally a mix of CD3+/CD4+ or CD3+/CD8+ lymphocytes. Only TIL from melanoma biopsies were found to be consistently cytolytic and, in many cases, lysed autologous tumor cells preferentially. Interestingly, TIL derived from extra-nodal sites of metastatic melanoma biopsies (subcutaneous, lung, bowel; 36 of 67, 54%) were more likely to have these cytolytic characteristics than TIL derived from tumor-involved lymph node biopsies (7 of 39, 18%). The present study summarizes 5 years of laboratory effort and validates the technologies developed for the large-scale growth and harvesting of TIL. In addition, it summarizes the laboratory effort supporting previously published clinical reports on TIL from our group.
Similar articles
- Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, Bansard JY, Levêque J, Guillé F, Patard JJ, Lesimple T, Catros-Quemener V. Bouet-Toussaint F, et al. Eur Cytokine Netw. 2000 Jun;11(2):217-24. Eur Cytokine Netw. 2000. PMID: 10903800 - Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
Malone CC, Schiltz PM, Mackintosh AD, Beutel LD, Heinemann FS, Dillman RO. Malone CC, et al. Cancer Biother Radiopharm. 2001 Oct;16(5):381-90. doi: 10.1089/108497801753354285. Cancer Biother Radiopharm. 2001. PMID: 11776755 - Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT, Pinto CE, Gifford JD, Kurnick JT, Kradin RL. Wong JT, et al. J Immunol. 1989 Nov 15;143(10):3404-11. J Immunol. 1989. PMID: 2509557 - White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C; Immunotherapy Task Force of the NCI Investigational Drug Steering Committee. Weber J, et al. Clin Cancer Res. 2011 Apr 1;17(7):1664-73. doi: 10.1158/1078-0432.CCR-10-2272. Epub 2011 Feb 15. Clin Cancer Res. 2011. PMID: 21325070 Review. - Tumor-Infiltrating Lymphocytes: Clinical Experience.
Besser MJ, Shapira-Frommer R, Schachter J. Besser MJ, et al. Cancer J. 2015 Nov-Dec;21(6):465-9. doi: 10.1097/PPO.0000000000000154. Cancer J. 2015. PMID: 26588677 Review.
Cited by
- Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies.
Aparicio B, Theunissen P, Hervas-Stubbs S, Fortes P, Sarobe P. Aparicio B, et al. Hum Vaccin Immunother. 2024 Dec 31;20(1):2303799. doi: 10.1080/21645515.2024.2303799. Epub 2024 Feb 12. Hum Vaccin Immunother. 2024. PMID: 38346926 Free PMC article. Review. - Recent Advances and Next Breakthrough in Immunotherapy for Cancer Treatment.
Yang L, Ning Q, Tang SS. Yang L, et al. J Immunol Res. 2022 Mar 18;2022:8052212. doi: 10.1155/2022/8052212. eCollection 2022. J Immunol Res. 2022. PMID: 35340585 Free PMC article. Review. - Multipeptide stimulated PBMCs generate TEM/TCM for adoptive cell therapy in multiple myeloma.
Vardam-Kaur T, Pathangey LB, McCormick DJ, Bergsagel PL, Cohen PA, Gendler SJ. Vardam-Kaur T, et al. Oncotarget. 2021 Sep 28;12(20):2051-2067. doi: 10.18632/oncotarget.28067. eCollection 2021 Sep 28. Oncotarget. 2021. PMID: 34611479 Free PMC article. - Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy.
Garcia-Aponte OF, Herwig C, Kozma B. Garcia-Aponte OF, et al. J Biol Eng. 2021 Apr 13;15(1):13. doi: 10.1186/s13036-021-00264-7. J Biol Eng. 2021. PMID: 33849630 Free PMC article. Review. - CD137+ T-Cells: Protagonists of the Immunotherapy Revolution.
Ugolini A, Nuti M. Ugolini A, et al. Cancers (Basel). 2021 Jan 26;13(3):456. doi: 10.3390/cancers13030456. Cancers (Basel). 2021. PMID: 33530328 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials